Dentsply Sirona Q2 2026 Earnings: Sales Decline as GAAP Margins Recover

Dentsply Sirona (Nasdaq: XRAY) reported Q2 2026 net sales of $898 million for the quarter ended June 30, down 4.1% from $936 million, while GAAP diluted EPS improved to $0.18 from a loss of $0.22 per share. GAAP gross margin rose to 54.9% and quarterly operating cash flow more than doubled to $99 million, but constant-currency sales declined 6.3% and adjusted operating profitability weakened.

Core Earnings Data

Foreign exchange supported reported revenue: the 4.1% reported decline widened to 6.3% on a constant-currency basis. The profit picture also differed sharply between GAAP and adjusted results, as the prior-year quarter included a $235 million goodwill and intangible asset impairment.

GAAP profitability returned to positive territory, while adjusted EBITDA declined and adjusted EPS was unchanged at the rounded reported amount. Cash generation improved substantially, although approximately $44 million of operating cash flow came from tariff refunds.

Business and Segment Performance

Three of Dentsply Sirona’s four segments reported lower sales. Orthodontic and Implant Solutions was the largest drag, accounting for about $29 million of the company’s roughly $38 million total revenue decline, while Wellspect Healthcare was the only segment to grow on both reported and constant-currency bases.

The Americas was the weakest region, with total sales down 10.7% as reported and 11.6% at constant currency. Orthodontic and Implant Solutions fell 27.1% in the Americas and 14.9% in APAC, while reported growth of 2.0% in EMEA became a 1.5% decline after removing currency effects.

Connected Technology Solutions performed better in APAC, where sales increased 8.8% as reported and 9.5% at constant currency. Wellspect also grew in EMEA and APAC, partially offsetting its 22.5% reported decline in the Americas.

Cash Flow and Balance Sheet

Operating cash flow increased by $51 million to $99 million. Management attributed the improvement primarily to approximately $44 million of tariff refunds and better management of inventory and accounts payable. Free cash flow reached $55 million after $44 million of quarterly capital expenditures, compared with $16 million after $32 million of capital expenditures a year earlier.

Cash and cash equivalents stood at $239 million on June 30, down from $326 million at the end of 2025. Current and long-term debt totaled about $2.22 billion, compared with about $2.33 billion at year-end. Dentsply Sirona also repurchased 1.3 million shares for approximately $12 million during the quarter.

GAAP Profit Rebounded, but Adjusted Operating Margin Fell

The return to GAAP operating income largely reflects an easier comparison with Q2 2025, when Dentsply Sirona recorded $235 million of goodwill and intangible asset impairments. No such impairment was recorded in Q2 2026. Excluding adjustments, operating income declined to $142 million from $170 million, and adjusted operating margin fell to 15.8% from 18.2%.

This occurred even as adjusted gross margin increased to 56.4% from 55.9%. At the reported level, selling, general and administrative expenses rose by $22 million to $364 million, while research and development expenses increased by $8 million to $45 million. These higher expenses, together with lower sales, limited the benefit of improved gross margins before impairment-related comparisons.

2026 Guidance

Dentsply Sirona maintained its full-year revenue and adjusted EPS ranges. The company specifically stated that benefits from tariff refunds are not included in its adjusted EPS outlook.

Management’s View

CEO Dan Scavilla said the company continues to execute its Return-to-Growth Action Plan. Current priorities include strengthening and expanding distributor relationships, realigning sales teams and reinvesting in the business.

Dentsply Sirona also announced an expanded partnership with Medline Sinclair, intended to broaden access to its Connected Technology Solutions portfolio across Canada. Management did not provide a quantified expected financial contribution from the partnership.

Recent Insider Transactions

The supplied insider dataset lists six purchases and four stock awards or grants among the latest ten records, all involving directors. However, its separate six-month summary reports no purchases or sales, creating an internal inconsistency; the table below reproduces the detailed records as provided without inferring insider sentiment.

Risks Investors Should Watch

• Underlying sales remain under pressure: Constant-currency revenue declined 6.3%, with particularly steep weakness in Orthodontic and Implant Solutions and the Americas.
• Gross-margin gains are not fully reaching operating profit: Adjusted gross margin improved, but adjusted operating income and margin declined amid lower sales and higher SG&A and R&D expenses.
• Part of the cash-flow improvement may not recur: Tariff refunds contributed approximately $44 million to quarterly operating cash flow, nearly matching the total $51 million year-over-year increase.
• Liquidity and debt remain important: Cash declined to $239 million from $326 million at year-end, while current and long-term debt remained above $2.2 billion.

Summary

Dentsply Sirona’s Q2 2026 results combined lower underlying sales with better GAAP margins and cash generation. The absence of prior-year impairment charges drove the GAAP profit turnaround, while adjusted operating results showed continued pressure from revenue contraction and higher expenses. Future results will depend on stabilizing the Orthodontic and Implant business, improving performance in the Americas and converting the company’s distributor and sales-force initiatives into sustainable growth.